S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
NASDAQ:ALXN

Alexion Pharmaceuticals Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$182.50
0.00 (0.00 %)
(As of 07/28/2021)
Add
Compare
Today's Range
$182.50
$182.50
50-Day Range
$179.45
$186.61
52-Week Range
$99.91
$187.45
Volume10 shs
Average Volume3.31 million shs
Market Capitalization$40.34 billion
P/E Ratio59.64
Dividend YieldN/A
Beta1.25

Receive ALXN News and Ratings via Email

Sign-up to receive the latest news and ratings for Alexion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Alexion Pharmaceuticals logo

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ALXN
CUSIP
01535110
Employees
3,837
Year Founded
1992

Sales & Book Value

Annual Sales
$6.07 billion
Cash Flow
$22.81 per share
Book Value
$53.24 per share

Profitability

Net Income
$603.40 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$40.34 billion
Next Earnings Date
N/A
Optionable
Optionable

Social Links


MarketRank

Overall MarketRank

1.93 out of 5 stars

Medical Sector

667th out of 1,359 stocks

Pharmaceutical Preparations Industry

316th out of 666 stocks

Analyst Opinion: 1.1Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -












Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions

Is Alexion Pharmaceuticals a buy right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last twelve months. There are currently 12 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Alexion Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALXN, but not buy additional shares or sell existing shares.
View analyst ratings for Alexion Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Alexion Pharmaceuticals?

Wall Street analysts have given Alexion Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Alexion Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced its quarterly earnings data on Thursday, April, 29th. The biopharmaceutical company reported $3.52 EPS for the quarter, topping analysts' consensus estimates of $3.16 by $0.36. The biopharmaceutical company earned $1.64 billion during the quarter, compared to analyst estimates of $1.58 billion. Alexion Pharmaceuticals had a trailing twelve-month return on equity of 23.43% and a net margin of 10.89%. The business's revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.22 EPS.
View Alexion Pharmaceuticals' earnings history
.

What price target have analysts set for ALXN?

15 equities research analysts have issued twelve-month target prices for Alexion Pharmaceuticals' shares. Their forecasts range from $73.00 to $205.00. On average, they anticipate Alexion Pharmaceuticals' stock price to reach $161.93 in the next twelve months. This suggests that the stock has a possible downside of 11.3%.
View analysts' price targets for Alexion Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Alexion Pharmaceuticals' key executives?

Alexion Pharmaceuticals' management team includes the following people:
  • Dr. Ludwig N. Hantson, CEO & Director (Age 58, Pay $4.25M)
  • Dr. Aradhana Sarin M.D., Exec. VP & CFO (Age 46, Pay $1.75M)
  • Mr. Brian M. Goff, Exec. VP and Chief Commercial & Global Operations Officer (Age 52, Pay $1.76M)
  • Ms. Ellen V. Chiniara J.D., Esq., Exec. VP, Chief Legal Officer & Corp. Sec. (Age 62, Pay $1.56M)
  • Dr. John J. Orloff, Exec. VP and Head of R&D (Age 64, Pay $1.83M)
  • Mr. Daniel A. Bazarko CPA, Chief Accounting Officer & Sr. VP
  • Mr. Christopher J. Stevo CFA, Head of Investor Relations
  • Ms. Indrani M. Lall Franchini, Exec. VP & Chief Compliance Officer (Age 49)
  • Megan Goulart, Sr. Director of Corp. Communications
  • Ms. Becky Lillie, Interim Chief Human Experience Officer

What is Ludwig Hantson's approval rating as Alexion Pharmaceuticals' CEO?

43 employees have rated Alexion Pharmaceuticals CEO Ludwig Hantson on Glassdoor.com. Ludwig Hantson has an approval rating of 75% among Alexion Pharmaceuticals' employees.

What other stocks do shareholders of Alexion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU), AbbVie (ABBV), Tesla (TSLA), Broadcom (AVGO), The Walt Disney (DIS) and Visa (V).

What is Alexion Pharmaceuticals' stock symbol?

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Who are Alexion Pharmaceuticals' major shareholders?

Alexion Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Crossmark Global Holdings Inc. (0.00%) and Crossmark Global Holdings Inc. (0.00%). Company insiders that own Alexion Pharmaceuticals stock include Bros Advisors Lp Baker, Daniel Bazarko and Tanisha Carino.
View institutional ownership trends for Alexion Pharmaceuticals
.

Which major investors are selling Alexion Pharmaceuticals stock?

ALXN stock was sold by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., and Crossmark Global Holdings Inc.. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Daniel Bazarko, and Tanisha Carino.
View insider buying and selling activity for Alexion Pharmaceuticals
or view top insider-selling stocks.

What is Alexion Pharmaceuticals' stock price today?

One share of ALXN stock can currently be purchased for approximately $182.50.

How much money does Alexion Pharmaceuticals make?

Alexion Pharmaceuticals has a market capitalization of $40.34 billion and generates $6.07 billion in revenue each year. The biopharmaceutical company earns $603.40 million in net income (profit) each year or $11.60 on an earnings per share basis.

How many employees does Alexion Pharmaceuticals have?

Alexion Pharmaceuticals employs 3,837 workers across the globe.

Does Alexion Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Alexion Pharmaceuticals: Achillion Pharmaceuticals, Achillion Pharmaceuticals Inc., Alexion 1609 Partners LP, Alexion Bermuda Holding ULC, Alexion Bermuda II L.P., Alexion Bermuda L.P., Alexion Bermuda Limited, Alexion Bermuda Partners L.P., Alexion Business Services Private Limited, Alexion Delaware Holding LLC, Alexion Europe SAS, Alexion Farmacêutica América Latina Serviços de Administração de Vendas Ltda., Alexion Farmacêutica Brasil Importação e Distribuição de Produtos e Serviços de Administração de Vendas Ltda., Alexion Holding B.V., Alexion Holding LLC, Alexion Ilaç Ticaret Limited Þirketi, Alexion Pharma Argentina SRL, Alexion Pharma Austria GmbH, Alexion Pharma Belgium Sprl, Alexion Pharma Canada Corp., Alexion Pharma Colombia SAS, Alexion Pharma Czech s.r.o, Alexion Pharma Development Unlimited Company, Alexion Pharma Foreign Holdings B.V., Alexion Pharma France SAS, Alexion Pharma GK, Alexion Pharma Germany GmbH, Alexion Pharma GmbH, Alexion Pharma Holding Unlimited Company, Alexion Pharma International Operations Unlimited Company, Alexion Pharma Israel Ltd., Alexion Pharma Italy Sarl, Alexion Pharma Korea LLC, Alexion Pharma LLC, Alexion Pharma Mexico S. de R.L. de C.V., Alexion Pharma Middle East FZ-LLC, Alexion Pharma Netherlands B.V., Alexion Pharma Nordics AB, Alexion Pharma Nordics Holding AB, Alexion Pharma OOO LLC, Alexion Pharma Spain S.L., Alexion Pharma Taiwan LTD, Alexion Pharma UK Ltd., Alexion Pharmaceuticals (Shanghai) Company Limited, Alexion Pharmaceuticals Australasia PTY LTD, Alexion Services Europe Sprl, Alexion Services Latin America Inc., Alexion US Holdings LLC, Alexion US1 LLC, Enobia Pharma Corp., Portola Deutschland GmbH, Portola FRG GmbH, Portola Italia S.r.l., Portola Netherlands B.V., Portola Pharma UK Ltd., Portola Pharmaceuticals Espana S.L, Portola Pharmaceuticals Inc., Portola Pharmaceuticals LLC, Portola Schweiz GmbH, Portola USA Inc., Portola Österreich GmbH, Savoy Therapeutics Corp., Synageva BioPharma Corp., Syntimmune, Syntimmune Ltd., TTM Europe Development AB, Taligen Therapeutics Inc., Wilson Therapeutics, Wilson Therapeutics AB, Wilson Therapeutics Incentive AB, and Wilson Therapeutics USA Inc..

When was Alexion Pharmaceuticals founded?

Alexion Pharmaceuticals was founded in 1992.

What is Alexion Pharmaceuticals' official website?

The official website for Alexion Pharmaceuticals is www.alexion.com.

Where are Alexion Pharmaceuticals' headquarters?

Alexion Pharmaceuticals is headquartered at 121 SEAPORT BOULEVARD, BOSTON MA, 02210.

How can I contact Alexion Pharmaceuticals?

Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected].


This page was last updated on 10/23/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.